BIO IP & Diagnostics Symposium

Patently BIOtech

BIO’s IP & Diagnostics Symposium (BIO IPDX) will review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. The program will review IP issues for both diagnostics generally and companion diagnostics. The program will also explore some of the potential regulatory dimensions. BIO aims to use this event to inform industry and government alike on how to move the science forward in the current climate.

Where & When

Monday, July 22, 2013

Hilton Alexandria Old Town Hotel │ 1767 King Street, Alexandria, VA 22314

Schedule of Events

*subject to change

Keynote Breakfast 8:00 am – 9:30 am

Jeffrey N. Peterson, Chief Executive Officer, Target Discovery, Inc.

Session One: Obtaining Patent Protection 9:30 am – 11:00 am

Sponsored by: McDonnell Boehnen Hulbert & Berghoff LLP

The first panel will discuss strategies for obtaining patent protection for diagnostic reagents and methods in light of recent decisions from the Supreme Court and Federal Circuit. The panel will provide views from in-house patent counsel, outside counsel and a representative from the US Patent and Trademark Office.

Moderator: Don Zuhn, McDonnell Boehnen Hulbert & Berghoff LLP

Panelists:

Kevin Noonan, McDonnell Boehnen Hulbert & Berghoff LLP

Duane Marks, Patent Counsel, Roche Diagnostics Operations, Inc.

Mary Till, Legal Advisor, Office of Patent Legal Administration, U.S. Patent & Trademark Office

Networking Break 11:00 am – 11:15 am

Session Two: Regulatory & Reimbursement 11:15 am – 12:30 pm

Sponsored by: Brinks Hofer Gilson & Lione

The panel will present an overview of the FDA review process for investigational drugs being developed with companion diagnostics, and tips for regulatory submissions specialists in preparing pre-IND packages, participating in meetings with the FDA, and preparing IND and NDA filings.  The panel will also address reimbursement strategies and potential issues for companies developing diagnostics.

Moderator: Jennifer L. Fox, Counsel, Brinks Hofer Gilson & Lione

Panelist:
Sheila D. Walcoff, Founding Principal, Goldbug Strategies LLC

Jeffrey N. Gibbs, Hyman, Phelps & McNamara, P.C.

Working Luncheon & Session Three: 12:30 pm – 2:15 pm

Business Development & Strategic Deals

Sponsored by: Sterne Kessler Goldstein & Fox LLP

The panel will discuss best practices in structuring commercial collaborations and transactions in the personalized medicine and companion diagnostics space and the impact of recent case law on patents in this industry.

Moderator: Eric Steffe, Director, Sterne Kessler Goldstein & Fox LLP

Panelists:

Tim Shea, Director, Sterne Kessler Goldstein & Fox LLP

Pia Maria Gargiulo, PhD, Managing Director, Companion Diagnostics, Precision for Medicine

Mollie Roth, Managing Partner, PGx Consulting

Zoran Zdraveski, Senior Director of Intellectual Property, Epizyme, Inc.

Closing Remarks       2:15 pm –2:45 pm

 

Registration

Although there is no fee to register, space is limited and you must reserve your seat. To promote a diverse audience, BIO asks that each company/organization register no more than two (2) people. Exceptions will be made for government attendees. To register, please contact Caroline Arrington at carrington@bio.org or (202) 962-9228.

Patently BIOtech  |  Email This Post  |  Printer Friendly
Tags: , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>